welcome to cyprotex

News

July 8, 2009 - Cyprotex hold their 4th North American Drug Discovery Workshop on the August 6th 2009

Cyprotex are holding their 4th North American Drug Discovery Workshop on Thursday August 6th 2009. This event is being staged at the Le Meridien Hotel in Cambridge, MA. 

There is an excellent line-up of speakers from Johnson and Johnson, Abbott Laboratories and Cara Therapeutics. Two of our Senior Scientists from Cyprotex will also be presenting. The topics being presented include transporters, reactive metabolites and PK/PD and PBPK modelling as well as more general presentations on ADME in drug discovery.

Attendees will have the opportunity to meet the CEO of Cyprotex, Dr Anthony Baxter, who will be chairing the event. The workshop provides the opportunity to mix and talk with scientists from a range of companies who have a like-minded interest in the drug discovery process. The presentations will provide an insight into the current research and the approaches being taken in a number of companies to address their drug discovery projects.

Registration for the event is free and Cyprotex will be providing a complementary breakfast and lunch. Further details of the event including the speaker list and titles plus information on location and registration can be found via the following link.

http://www.cyprotex.com/mailer/20090806ddw/

For further information:
Cyprotex PLC

Swadipa Das, Business Development & Marketing
Tel: +44 (0)1625 505 100
s.das@cyprotex.com
www.cyprotex.com

view all the latest news +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Contact us for more information on Cyprotex Discovery, including our extensive range of ADMET/PK services
and pricing.

contact
careerscontactlegalprivacy
This website was last updated
on 31st August 2010
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.